|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
118,790,000 |
Market
Cap: |
42.71(M) |
Last
Volume: |
19,275,386 |
Avg
Vol: |
8,941,637 |
52
Week Range: |
$0.3595 - $0.3595 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Novavax is a biotechnology company that promotes improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, NVX-CoV2373, and its primary influenza vaccine candidate, NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 and NanoFlu include the use of Co.'s proprietary Matrix-M adjuvant.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
6,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$43,042 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
3 |
Total Shares Sold |
68,716 |
68,716 |
68,716 |
68,716 |
Total Sell Value |
$961,682 |
$961,682 |
$961,682 |
$961,682 |
Total People Sold |
2 |
2 |
2 |
2 |
Total Sell Transactions |
3 |
3 |
3 |
3 |
End Date |
2024-04-07 |
2024-01-05 |
2023-07-07 |
2022-07-07 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Glenn Gregory M |
President, R&D |
|
2021-06-15 |
4 |
D |
$187.07 |
$28,809 |
D/D |
(154) |
7,476 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-06-15 |
4 |
OE |
$5.95 |
$138,685 |
D/D |
10,535 |
7,630 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-06-15 |
4 |
AS |
$183.53 |
$1,094,130 |
D/D |
(5,716) |
2,811 |
|
- |
|
Evans Gray C |
Director |
|
2021-06-01 |
4 |
S |
$146.50 |
$91,563 |
I/I |
(625) |
0 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-05-28 |
4 |
AS |
$147.85 |
$431,748 |
D/D |
(2,895) |
275 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-05-28 |
4 |
OE |
$5.95 |
$42,933 |
D/D |
2,895 |
3,170 |
|
- |
|
King Rachel K. |
Director |
|
2021-05-19 |
4 |
B |
$139.64 |
$97,748 |
D/D |
700 |
2,800 |
2.39 |
- |
|
Glenn Gregory M |
President, R&D |
|
2021-05-19 |
4 |
AS |
$138.29 |
$339,066 |
D/D |
(2,385) |
2,811 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-05-17 |
4 |
D |
$140.16 |
$312,417 |
D/D |
(2,229) |
5,196 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-05-17 |
4 |
D |
$140.16 |
$28,733 |
D/D |
(205) |
7,425 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-05-17 |
4 |
OE |
$5.95 |
$138,577 |
D/D |
10,531 |
7,630 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-05-17 |
4 |
AS |
$131.50 |
$765,267 |
D/D |
(5,712) |
2,811 |
|
- |
|
Trizzino John |
EVP, CCO, CBO & Interim CFO |
|
2021-05-07 |
4 |
AS |
$176.60 |
$33,559 |
D/D |
(190) |
287 |
|
- |
|
Trizzino John |
EVP, CCO, CBO & Interim CFO |
|
2021-05-05 |
4 |
D |
$171.74 |
$30,913 |
D/D |
(180) |
477 |
|
- |
|
Trizzino John |
EVP, CCO, CBO & Interim CFO |
|
2021-05-05 |
4 |
D |
$171.74 |
$2,404 |
D/D |
(14) |
657 |
|
- |
|
Trizzino John |
EVP, CCO, CBO & Interim CFO |
|
2021-05-05 |
4 |
OE |
$5.95 |
$50,160 |
D/D |
3,406 |
671 |
|
- |
|
Trizzino John |
EVP, CCO, CBO & Interim CFO |
|
2021-05-05 |
4 |
AS |
$163.03 |
$560,471 |
D/D |
(3,022) |
287 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-04-30 |
4 |
AS |
$236.27 |
$694,317 |
D/D |
(2,895) |
275 |
|
- |
|
Herrmann John A Iii |
EVP, Chief Legal Officer |
|
2021-04-30 |
4 |
OE |
$5.95 |
$42,892 |
D/D |
2,895 |
3,170 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-04-19 |
4 |
AS |
$213.79 |
$531,052 |
D/D |
(2,417) |
2,811 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-04-15 |
4 |
D |
$202.09 |
$456,723 |
D/D |
(2,260) |
5,228 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-04-15 |
4 |
D |
$202.09 |
$28,697 |
D/D |
(142) |
7,488 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-04-15 |
4 |
OE |
$5.95 |
$1,083,775 |
D/D |
10,531 |
7,630 |
|
- |
|
Glenn Gregory M |
President, R&D |
|
2021-04-15 |
4 |
AS |
$196.77 |
$1,144,387 |
D/D |
(5,712) |
2,811 |
|
- |
|
Trizzino John |
EVP, Chief Commercial Officer |
|
2021-04-07 |
4 |
AS |
$178.03 |
$34,004 |
D/D |
(191) |
287 |
|
- |
|
460 Records found
|
|
Page 10 of 19 |
|
|